Genomind, a King of Prussia, Penn.-based platform that uses genetic analysis to guide mental health treatment, has partnered with NeuroFlow, a Philadelphia-based software company providing remote monitoring and artificial intelligence-enabled behavioral health integration across care settings.
Joining forces will allow the companies to integrate Genomind's mental health pharmacogenomics service and resulting patient insights, along with NeuroFlow's progress tracking tools, into primary care, pain management and other clinical settings. This data-driven approach will enable physicians to better monitor patients' genetic risks and treatment adherence, potentially leading to cost reductions and improved outcomes.
"Mental healthcare is in crisis, with reduced access to care, higher costs and poorer outcomes. We believe that progressive ideas are key to addressing this impasse and we are committed to being part of the solution," said Shawn Patrick O'Brien, CEO of Genomind. "Our collaboration with NeuroFlow is a strategic fit of complementary missions — using data-driven innovations to get patients the care they need faster."